Kelly A. Demerino
Corporate Officer/Principal en NUVO PHARMACEUTICALS INC. .
Cargos activos de Kelly A. Demerino
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/01/2021 | - |
| Comptroller/Controller/Auditor | 01/01/2019 | 01/01/2020 | |
| Director Financiero/CFO | 01/01/2020 | 01/01/2021 |
Historial de carrera de Kelly A. Demerino
Formación de Kelly A. Demerino.
| Mount Allison University | Undergraduate Degree |
Estadísticas
Internacional
| Canadá | 3 |
Operativa
| Comptroller/Controller/Auditor | 1 |
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Kelly A. Demerino
- Experiencia
